An association between fatigue and overexpression of 2′-5′-oligoadenylate synthetase 2 (OAS2), a gene linked to chronic fatigue syndrome, was noted in cancer patients receiving chronic IFNα therapy [35]. This evidence concerns the gene OAS2 and myalgic encephalomeyelitis/chronic fatigue syndrome.